RxDoctor Payments Data

Mahmood Fathollazadeh, PA

Physician Assistant · Colton, CANPI 1386711158

Payments from drug & device makers

$5,207in general payments, 2019–2025

Across 302 payments — averaging $17.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$758
  • Boston Scientific$706
  • Collegium Pharmaceutical, Inc.$570
  • Merck$282
  • Pfizer$248
  • Biodelivery Sciences International, Inc.$235
  • plus $2K from 30 others

What the payments were for

  • Food & beverage$5,182100%
  • Education$240%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,207 in reported general payments places this provider in the 90th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$57,097
Medicare patients
207
Services billed
753

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl88$80,578
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen2,368$69,593
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen659$61,680
Levorphanol Tartrate17$51,559
OxycontinOxycodone Hcl50$25,609
Buprenorphine69$17,989
Emgality PenGalcanezumab-Gnlm21$16,345
LyricaPregabalin15$13,613
Lidocaine114$10,394
Oxycodone Hcl529$9,989
MovantikNaloxegol Oxalate22$8,952
Gabapentin653$7,627
Morphine Sulfate ErMorphine Sulfate235$6,425
HorizantGabapentin Enacarbil11$5,892
Hydromorphone Hcl249$4,753

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$570$80,57888 claims
Virtus Pharmaceuticals LLCLevorphanol Tartrate$81$51,55917 claims
PfizerLyrica$248$13,61315 claims
Arbor Pharmaceuticals, Inc.Horizant$82$5,89211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Colton

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →